PHARVARIS N V's ticker is PHVS and the CUSIP is N69605108. A total of 22 filers reported holding PHARVARIS N V in Q3 2023. The put-call ratio across all filers is - and the average weighting 4.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $66,941,861 | +25.8% | 3,207,564 | -5.3% | 0.01% | +50.0% |
| Q2 2023 | $53,212,237 | +2.6% | 3,387,157 | -48.9% | 0.00% | +100.0% |
| Q1 2023 | $51,850,322 | +39.0% | 6,630,476 | +100.0% | 0.00% | -50.0% |
| Q4 2022 | $37,296,427 | +40.1% | 3,315,238 | +0.0% | 0.00% | +33.3% |
| Q3 2022 | $26,620,000 | -63.7% | 3,315,188 | 0.0% | 0.00% | -57.1% |
| Q2 2022 | $73,265,000 | +18.2% | 3,315,188 | 0.0% | 0.01% | +40.0% |
| Q1 2022 | $61,994,000 | +18.9% | 3,315,188 | +0.6% | 0.01% | +25.0% |
| Q4 2021 | $52,129,000 | -8.8% | 3,295,109 | -0.5% | 0.00% | -20.0% |
| Q3 2021 | $57,146,000 | -3.5% | 3,312,859 | +1.7% | 0.01% | 0.0% |
| Q2 2021 | $59,202,000 | -23.8% | 3,258,217 | +17.7% | 0.01% | -28.6% |
| Q1 2021 | $77,663,000 | – | 2,767,727 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 3,743,450 | $78,125,802 | 43.39% |
| venBio Partners LLC | 4,264,672 | $89,003,705 | 25.24% |
| Bain Capital Life Sciences Investors, LLC | 4,784,674 | $99,856,146 | 11.17% |
| 5AM Venture Management, LLC | 587,600 | $12,263,212 | 3.53% |
| VR Adviser, LLC | 1,563,513 | $32,630,516 | 3.44% |
| Novo Holdings A/S | 1,329,325 | $27,743,013 | 2.05% |
| Cormorant Asset Management, LP | 1,361,460 | $28,413,670 | 1.66% |
| GENERAL ATLANTIC, L.P. | 4,406,252 | $91,958,479 | 1.42% |
| Foresite Capital Management V, LLC | 33,142 | $691,674 | 1.10% |
| Soleus Capital Management, L.P. | 343,975 | $7,178,758 | 0.66% |